NEW YORK (GenomeWeb News) – Lineagen today announced it completed a Series C financing round that raised $3.5 million.

The Salt Lake City-based molecular diagnostic firm also said that it received multiple term sheets for multimillion dollar senior secured debt facilities, including one that it intends to close as part of the Series C financing. It also announced it is converting $12.6 million in outstanding promissory notes into shares of Series B preferred stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.